Penumbra (PEN) Receives Buy Rating from RBC Capital with $325 Price Target
ByAinvest
Wednesday, Aug 13, 2025 6:46 pm ET1min read
PEN--
The latest earnings report highlights Penumbra's strong performance in the healthcare sector. The company's revenue grew by 13.4% compared to the same quarter last year, with a net profit margin of 11.54%. The company's earnings per share (EPS) for the quarter was $0.86, beating the consensus estimate of $0.81 by $0.05 [2].
Chadha's positive outlook is further backed by the company's strong cash flow growth, which has been 8.3% year-over-year, outperforming the industry average of 2.9% [1]. Additionally, the company's historical cash flow growth rate over the past 3-5 years has been 21.3%, compared to the industry average of 9% [1].
The company's earnings estimate revisions have also been positive, with a 0.9% upward revision in the current-year earnings estimate over the past month [1]. This trend suggests that analysts are increasingly optimistic about Penumbra's future prospects.
Penumbra's strong performance and positive analyst sentiment make it an attractive investment opportunity. However, investors should always conduct their own research and consider their risk tolerance before making any investment decisions.
References:
[1] https://www.nasdaq.com/articles/rbc-bearings-rbc-solid-growth-stock-3-reasons-think-yes
[2] https://www.marketbeat.com/instant-alerts/filing-informed-momentum-co-llc-makes-new-399-million-investment-in-penumbra-inc-nysepen-2025-08-12/
RBC Capital maintains a Buy rating for Penumbra with a price target of $325. Analyst Singh Chadha has a 48.51% success rate and covers healthcare stocks like Medtronic and Globus Medical. Penumbra's latest earnings report showed a quarterly revenue of $339.46 million and a net profit of $45.27 million.
RBC Capital has maintained its Buy rating for Penumbra (NYSE:PEN), with a price target of $325. This rating comes from analyst Singh Chadha, who has a 48.51% success rate and covers healthcare stocks such as Medtronic and Globus Medical. Chadha's optimism is supported by Penumbra's latest earnings report, which showed a quarterly revenue of $339.46 million and a net profit of $45.27 million [2].The latest earnings report highlights Penumbra's strong performance in the healthcare sector. The company's revenue grew by 13.4% compared to the same quarter last year, with a net profit margin of 11.54%. The company's earnings per share (EPS) for the quarter was $0.86, beating the consensus estimate of $0.81 by $0.05 [2].
Chadha's positive outlook is further backed by the company's strong cash flow growth, which has been 8.3% year-over-year, outperforming the industry average of 2.9% [1]. Additionally, the company's historical cash flow growth rate over the past 3-5 years has been 21.3%, compared to the industry average of 9% [1].
The company's earnings estimate revisions have also been positive, with a 0.9% upward revision in the current-year earnings estimate over the past month [1]. This trend suggests that analysts are increasingly optimistic about Penumbra's future prospects.
Penumbra's strong performance and positive analyst sentiment make it an attractive investment opportunity. However, investors should always conduct their own research and consider their risk tolerance before making any investment decisions.
References:
[1] https://www.nasdaq.com/articles/rbc-bearings-rbc-solid-growth-stock-3-reasons-think-yes
[2] https://www.marketbeat.com/instant-alerts/filing-informed-momentum-co-llc-makes-new-399-million-investment-in-penumbra-inc-nysepen-2025-08-12/

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet